- Home
- ACIC vs ACRS Comparison
ACIC vs ACRS Comparison
Compare ACIC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ACRS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.7M | 529.9M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACIC | ACRS |
|---|---|---|
| Price | $10.39 | $4.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | 245.9K | ★ 2.5M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | 39.61 | ★ 69.01 |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $335,439,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.01 | $2.25 |
| 52 Week High | $13.06 | $6.60 |
Technical Indicators
Market Signals| Indicator | ACIC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 50.83 |
| Support Level | $9.79 | $3.24 |
| Resistance Level | $11.48 | $4.22 |
| Average True Range (ATR) | 0.37 | 0.29 |
| MACD | -0.12 | 0.11 |
| Stochastic Oscillator | 36.43 | 68.23 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.